

PRIVATE INSURANCE COVERAGE CONFIRMED FOR CXBLADDER

Cxbladder Now Covered by nib Health Insurance

Cancer diagnostics company, Pacific Edge (NZX:PEB) has advised that its Cxbladder diagnostics tests have been approved for reimbursement by a second major health insurance provider, nib Health Insurance in New Zealand.

Cxbladder is now covered for specialist referral under nib's health policies which include benefits for specialist consultations and diagnostic investigations. This includes patients undergoing investigation for haematuria (blood in the urine) as well as for bladder cancer patients undergoing post-treatment surveillance. nib is initially covering Cxbladder for a six month period, with claims to be reviewed by a Clinical Adviser.

Brent Pownall, Commercial Director for Pacific Edge Diagnostics noted that nib is the second insurance provider to confirm coverage of Cxbladder where requested by a specialist. "Both Cxbladder Triage and Cxbladder Monitor offer an alternative to cystoscopy where the urologist determines the invasive procedure may not be necessary.

"Through the urologist, nib's customers can now get access to what we consider to be the most effective and non-invasive bladder cancer detection and management technology available."

David Darling, CEO of Pacific Edge, said: "We are seeing a groundswell in terms of uptake in the New Zealand market by both private and public healthcare providers. The increase in coverage by insurance providers complements the recognition Cxbladder is receiving in the public healthcare sector, as seen with the recent commercial agreement with Canterbury District Health Board.

"Our goal is to provide all New Zealanders with access to Cxbladder, whether it be through the private or public health system. We are looking to bring on other private insurance providers and expand the access already available through some District Health Boards."

For more information, contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW

www.pacifiedge.co.nz

www.pacifiedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies. Pacific Edge has three proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Detect is available through the company's dedicated CLIA certified laboratories for customers in New Zealand, Australia and the USA. Cxbladder Triage is available in New Zealand and Australia. Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated being available in the US in 2016.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with hematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories. Cxbladder Detect provides physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

Refer to www.cxbladder.com for more information.